It can be concluded that EAM-2201 has the prospective to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes. EAM-2201 was incubated with human hepatocytes for three h within a CO2 incubator as well as https://hemalchem.com/product-category/am-series/